✦ LIBER ✦

Treatment of advanced and recurrent ovarian carcinoma with cyclophosphamide, doxorubicin, and cisplatin

✍ Scribed by Jerome L. Belinson; Maura McClure; Takamaru Ashikaga; Irwin H. Krakoff

Publisher: John Wiley and Sons
Year: 1984
Tongue: English
Weight: 650 KB
Volume: 54
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19841101)54:9<1983::aid-cncr2820540933>3.0.co;2-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cyclophosphamide, Doxorubicin, and Cispl

Cyclophosphamide, Doxorubicin, and Cisplatin Combined in the Treatment of Advanced Sarcomas

✍ Edmonson, John H. ;Hahn, Richard G. ;Schutt, Allan J. ;Bisel, Harry F. ;Ingle, J 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB

Twenty-five patients with evaluable histologically confirmed inoperable metastatic sarcomas were treated once every four weeks with cyclophosphamide, doxorubicin, and cisplatin in doses of 400, 40, and 60 mg/m2, respectively. Cyclophosphamide and doxorubicin were given by rapid intravenous injection

Cyclophosphamide, doxorubicin, and cispl

Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin

✍ Arnon I. Dreyfuss; John R. Clark; Barbara G. Fallon; Marshall R. Posner; Charles 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 408 KB 👁 2 views

Thirteen patients with carcinomas of major and minor salivary gland origin (nine adenoid cystic carcinomas and four adenocarcinomas) were treated with cyclophosphamide (500 mg/m2), doxorubicin (50 mg/m2), and cisplatin (50 mg/m2) (CAP) by intravenous injections on the first day of a 28-day regimen.

A randomized trial of cyclophosphamide a

A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study

✍ George Omura; John A. Blessing; Clarence E. Ehrlich; Alexander Miller; Edgardo Y 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 593 KB

Treatment of advanced ovarian cancer wit

Treatment of advanced ovarian cancer with cisplatin, adriamycin, and cyclophosphamide: Effect of treatment and incidence of intracranial metastases

✍ G. Thomas Budd; Kenneth D. Webster; Ronald R. Reimer; Pierre Martimbeau; Robert 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 324 KB

A retrospective analysis of 42 patients with stage 111, IV, or recurrcnt epithelial ovarian carcinoma treated with monthly cisplatin, Adriamycin, and cyclophosphamide (PAC) was made. Of 36 patients with measurable disease, 18 (50%) achieved a clinical complete response (CR) and 12 (33%) achieved a p

Mitotane associated with etoposide, doxo

Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma

✍ Alfredo Berruti; Massimo Terzolo; Anna Pia; Alberto Angeli; Luigi Dogliotti 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

BACKGROUND. The use of either mitotane or chemotherapy in the treatment of advanced adrenocortical carcinoma (ACC) has led to scanty and controversial results. The recent finding that mitotane is able to reverse in vitro multidrug resistance has provided a rational basis for combining this agent wit

Development of leukemia after doxorubici

Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer

✍ S. K. Chambers; R. L. Chopyk; J. T. Chambers; P. E. Schwartz; T. P. Duffy 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB 👁 2 views